Innovating Cancer Research: trends, challenges & future perspectives

Sales Have Ended

Registrations are closed
Thank you for registering for the OncoStars launch event, we look forward to seeing you there!

Event Information

Share this event

Date and Time

Location

Location

Francis Crick Institute

1 Midland Road

London

NW1 1AT

United Kingdom

View Map

Sales Have Ended

Registrations are closed
Thank you for registering for the OncoStars launch event, we look forward to seeing you there!
Event description
OncoStars Launch - Innovating Cancer Research: trends, challenges and future perspectives.

About this Event

PanaceaStars are partnering with Cancer Research UK to deliver Oncostars: an engagement, training and translation platform for researchers working in the field of oncology. More information about the partnership can be found at our website.

To lauch the initiative, we will be co-hosting an event at the Francis Crick Institute on Tuesday 5th November.

The event aims to bring together experts from academia, tech transfer, investment, pharma, biotech & entrepreneurship to discuss innovation in oncology from their different perspectives, touching on the current trends in the field, the challenges faced and what more can be done to foster the development of young sci-entrepreneurs in Oncology.

Each of our expert speakers will give a 10-minute presentation on their perspectives, followed by a panel discussion, mediated by a member of the PanaceaStars team, which will be opended up to the audience. The evening will conclude with a networking drinks reception.

Agenda

17:30 - Registration

17:45 - Introduction from Panacea Stars, Deep Science Ventures and Cancer Research UK

18:00 - Tony Hickson - Chief Business Officer @ Cancer Research UK

18:10 - Kevin Johnson - Co-founder and Partner @ Medicxi

18:20 - Phil Coxon - Associate Director of Bus Dev in Oncology @ AstraZeneca

18:30 - John Cassidy - Co-founder and CEO @ Cambridge Cancer Genomics

18:40 - Sophia Karagiannis - Scientific founder @ IGEM therapeutics

18:50 - Panel discussion

19:30 - Networking drinks

Speakers Bios

Tony Hickson

Tony Hickson is the Chief Business Officer for Cancer Research UK. He leads the Commercial Partnerships team responsible for the commercialisation of IP from CRUK funded projects, new start-up creation, licences and corporate alliances.

Prior to this Tony was the Managing Director of Imperial Innovations Ltd, responsible for intellectual property sourcing, licensing and spin-out creation for technologies arising from Imperial College London. Tony has sat on the Executive Committee of IP Group and spent 5 years as an executive director on the board of Touchstone Innovations PLC, a company listed on the London Stock exchange investing in deep science projects from UK universities. Prior to joining Imperial Innovations, Tony had acquired 15 years of commercial and business development experience in bioscience companies including Wellcome Group R&D, Murex Biotech, Abbott Laboratories and Kalibrant Limited. He has acted as a board director or observer for a number of start-up companies including Polytherics (now Abzena), Catapult Therapy TCR, Zihipp and Precision Robotics, and was instrumental in the creation & development of companies such as Thiakis (sold to Wyeth/Pfizer in 2008), Respivert (sold to J&J in 2010), Circassia (listed on LSE in 2014), EMcision (sold to Boston Scientific in 2018) and Cell Medica (in advanced clinical studies).

Tony has sat on the IP boards of two European Institutes of Technology (Healthcare and Climate Change), is a member of the BBSRC industry advisory panel and a board director of PraxisUnico. He has a diploma in company direction from the Institute of Directors and is a Certified Licensing Professional.

Kevin Johnson

Kevin Johson is a co-founder and Partner at Medicxi. Prior to Medicxi, Kevin was a Partner at Index Ventures for 13 years, having joined the firm in 2003. Kevin originated Index’s first asset-centric investment in PanGenetics (acquired by Abbott) and led Medicxi’s investment in Impact Biomedicines (acquired by Celgene). Kevin currently serves on the boards of a number of portfolio companies, including Levicept, Superx, Capella Bioscience, UltraHuman, Apcintex and Breakpoint Therapeutics.

Prior to joining Index, Kevin was with Cambridge Antibody Technology (CAT). During his tenure at CAT, he was appointed Head of Research in 1994 and then Research Director and Chief Technology Officer in 1997. Kevin led the development of CAT's platform technologies and oversaw their application in the discovery of a number of human antibodies - two of which are now marketed worldwide: Humira (by Abbott Pharmaceuticals) and Benlysta (by GlaxoSmithKline). Kevin was part of the management team that floated CAT on the London Stock Exchange (subsequently acquired by AstraZeneca).

Kevin received a BSc in Molecular Biology from Edinburgh University and a PhD in Pathology from Cambridge University. He also acts as chairman of Crescendo Biologics and sits on the strategic advisory committee of Hilleman Laboratories.

Phil Coxon

Phil Coxon is Associate Director, Business Development - Oncology Business Development and Licensing at AstraZeneca, a global pharmaceutical company operating in more than 100 countries worldwide. In this role he is involved in global licensing and partnering with regards to oncology assets in early clinical development and research.

Phil has a wealth of experience in technology transfer and business development. He spent four years at Teva Pharmaceuticals in Amsterdam where he was a key member of the Global Business Development and Strategy team, responsible for leading in-licensing, out-licensing and divestment transactions of clinical stage and commercial opportunities in oncology, CNS and respiratory. Prior to joining Teva, Phil worked at LifeArc, a leading medical research charity, where he had responsibility for promoting LifeArc’s collaborative drug discovery capabilities to potential partners, and both identifying and evaluating new collaborative drug discovery projects from within academia and industry.

Phil has a BSc in Biochemistry and Physiology from University of Leeds and a PhD in Molecular Genetics from The Institute of Cancer Research.

John Cassidy

John Cassidy is Co-founder and CEO at Cambridge Cancer Genomics (CCG.ai), a precision AI startup transforming the ability of oncologists to provide effective, personalised cancer treatment for everyone. John holds a PhD in functional genomics from the University of Cambridge and a Masters in Pharmacology from the University of Glasgow. His research career in academia (CRUK) and industry (MedImmune) focused on understanding how tumours evolve and become resistant to treatment. John is actively involved in the biotech startup community as a Venture Partner at the Pioneer Fund, Director of SiliconBio and a lecturer at Anglia Ruskin University.

Sophia Karagiannis

Sophia Karagiannis is scientific founder of IGEM Therapeutics Ltd, a King’s College London (KCL) spinout and the first immuno-oncology company focused on IgE immunotherapies. Whilst maintaining an ongoing collaboration with IGEM, Sophia is a Professor of Translational Cancer Immunology and Immunotherapy at KCL. She heads a cancer antibody discovery team focused on designing novel agents for skin, ovarian and breast cancers and striving to understand the cross-talk between patient immune cells and tumours. Her group is the first to design and translate an IgE class antibody recognising a cancer antigen to clinical study. Additionally, she co-founded and Chairs the Task Force on AllergoOncology and her group collaborates closely with the Cancer Research UK Centre for Drug Development.

About PanaceaStars

PanceaStars is a health and life sciencestechnology translation platform. Wecollaborate with the most exciting scientrepreneursto help transform boldvisions into thriving companies thatimprove people’s lives. Whether you havethe seed of a scientific innovation or awell-developed proof-of-concept, ourmulti-phase framework is designed to helpyou translate your idea into a successfulbusiness. Find out more here.

About Cancer Research UK

Cancer Research UK is the world’sleading cancer charity dedicated to savinglives through research and awareness.We carry out scientific research to helpprevent, diagnose and treat cancer. Wehave discovered new ways to beat cancerthat together have saved hundreds ofthousands of lives across the world. Findout more here.

Date and Time

Location

Francis Crick Institute

1 Midland Road

London

NW1 1AT

United Kingdom

View Map

Save This Event

Event Saved